Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

RIFM Adopts BlueScreen HC™ for Early Genetic Toxicology Screening of Fragrance Materials

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
As part of its continuing mission to ensure the safety of fragrance ingredients, the RIFM has incorporated early screening with BlueScreen™ into its genotoxicity profiling regime.

RIFM is a non-profit research institute whose purpose is to gather and analyse scientific data, engage in testing and evaluation, distribute information, cooperate with official agencies and to encourage uniform safety standards related to the use of fragrance ingredients.   To meet these goals, RIFM takes advantage of recent innovations in risk assessment methodology.  The use of BlueScreen™ HC provides accurate, sensitive results that are efficiently integrated into RIFM’s testing cascade and enable more efficient fragrance material evaluation.

BlueScreen™ HC is a highly specific, sensitive human cell based assay used to screen chemicals for their potential to cause damage to DNA: a property known as genotoxicity.  Based on technology already used in the pharmaceutical industry, BlueScreen HC is used to provide a rapid assessment of potential hazard across diverse chemical collections in the assessment of new chemicals that are candidates for product development.

The assay evaluates the up-regulation of a key gene’s, GADD45a, response to a chemical that causes damage to, or interferes with, DNA.  It measures the luminescence generated from the enzyme Gaussia Luciferase from the marine crustacean Gaussia princeps.

The gene is incorporated into the human TK6 cells used in the assay and linked to GADD45a production.

RIFM and the originators of BlueScreen HC, Gentronix Limited are working closely on the assessment of fragrance materials for use in a wide range of consumer products.

“We found BlueScreen™ HC to be a very useful tool in our fragrance material evaluation process” said RIFM President, Dr. David Wilcox.

Gentronix Commercial Director, Dr. Steve Beasley said: “We have been impressed with the scientific rigor that RIFM brings to the safety evaluation of fragrance materials and their assessment of new technologies such as BlueScreen HC. We look forward to continuing this important collaboration.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Development in Preventing Macular Degeneration
Following macular degeneration insight, promising drugs to prevent vision loss have been identified.
Improving Tumour Therapy with Nanoparticles
UHN nanoparticle called PEARLs is a promising utilisation of photo-thermal therapy for cancer treatment.
New Antidepressant Treatment Discovered
Scientists have demonstrated how gene therapy could lead to new treatments for depression.
Cellular Origin of Skin Cancer Identified
Scientists have identified ‘cell of origin’ in the most common form of skin cancer, and followed the process that leads to tumour growth.
Enhancing Drug Safety with a Web-Based Data Tool
Online and open-access tool allows anyone to find, combine and analyse FDA drug information.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!